Anesthesiology and Pain Medicine

Published by: Kowsar

Use of Oxycodone in Pain Management

Mohammad Moradi 1 , Sara Esmaeili 1 , Saeed Shoar 1 and Saeid Safari 3 , *
Authors Information
1 Development Association of Clinical Studies (DACS), Tehran University of Medical Sciences (TUMS), Tehran, Iran
3 Department of Anesthesiology, Rasoul Akram Medical Center, Tehran university of Medical Sciences (TUMS), Tehran, Iran
Article information
  • Anesthesiology and Pain Medicine: March 22, 2012, 1 (4); 262-264
  • Published Online: March 22, 2012
  • Article Type: Rapid Communication
  • Received: February 17, 2012
  • Revised: February 25, 2012
  • Accepted: March 2, 2012
  • DOI: 10.5812/aapm.4529

To Cite: Moradi M, Esmaeili S, Shoar S, Safari S. Use of Oxycodone in Pain Management, Anesth Pain Med. 2012 ; 1(4):262-264. doi: 10.5812/aapm.4529.

Abstract
Copyright © 2012, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Acknowledgements
Footnotes
References
  • 1. Sneader W. Drug discovery: a history. 2005;
  • 2. General Accounting Office (GAO). . Prescription drugs oxycontin abuse and diversion and efforts to address the problem. 2003 Dec; -04-110 Contract No.: Document Number
  • 3. Drug Patent Expirations and Intelligence Drug Patent Watch Preview Section. Details for oxycontin. ; . 2012;
  • 4. Poyhia R, Seppala T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992; 33(6): 617-21[PubMed]
  • 5. Kirvela M, Lindgren L, Seppala T, Olkkola KT. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth. 1996; 8(1): 13-8[PubMed]
  • 6. Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010; 70(1): 78-87[DOI][PubMed]
  • 7. Pattinson KT. . Opioids and the control of respiration. Br J Anaesth. 2008; 100(6): 747-58
  • 8. Kalso E. Oxycodone. J Pain Symptom Manage. 2005; 29(5 Suppl)-56[DOI][PubMed]
  • 9. Hamunen K, Paakkari P, Kalso E. Trends in opioid consumption in the Nordic countries 2002-2006. Eur J Pain. 2009; 13(9): 954-62[DOI][PubMed]
  • 10. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008; 24(1): 175-92[DOI][PubMed]
  • 11. FDA. . Oxycodone Professional Monograph. 2010;
  • 12. Fredheim OM, Dale O, Kaasa S, Borchgrevink PC. [Morphine or oxycodone tablets for pain?]. Tidsskr Nor Laegeforen. 2010; 130(15): 1479-81[DOI][PubMed]
  • 13. King SJ, Reid C, Forbes K, Hanks G. A systematic review of oxycodone in the management of cancer pain. Palliat Med. 2011; 25(5): 454-70[DOI][PubMed]
  • 14. Olesen AE, Staahl C, Arendt-Nielsen L, Drewes AM. Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study. Br J Clin Pharmacol. 2010; 70(2): 189-200[DOI][PubMed]
  • 15. Sumitani M, Yamada Y. [Clinical efficacy of oxycodone against cancer-related pain with a wide variety of pathophysiologies]. Gan To Kagaku Ryoho. 2011; 38(6): 977-82[PubMed]
  • 16. Inoue K, Nagai S, Kaneko S, Uchida S, Hayashi Y, Higuchi T, et al. [Efficacy of oxycodone against anti-cancer agent-induced pain in breast cancer patients during adjuvant treatment before and after surgery]. Gan To Kagaku Ryoho. 2011; 38(7): 1137-42[PubMed]
  • 17. Staahl C, Christrup LL, Andersen SD, Arendt-Nielsen L, Drewes AM. A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Pain. 2006; 123(1-2): 28-36[DOI][PubMed]
  • 18. Staahl C, Dimcevski G, Andersen SD, Thorsgaard N, Christrup LL, Arendt-Nielsen L, et al. Differential effect of opioids in patients with chronic pancreatitis: an experimental pain study. Scand J Gastroenterol. 2007; 42(3): 383-90[DOI][PubMed]
  • 19. Richards P, Riff D, Kelen R, Stern W. Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination (MoxDuo) in the treatment of postoperative pain. J Opioid Manag. 2011; 7(3): 217-28[PubMed]
  • 20. Roland CL, Setnik B, Cleveland JM, Brown DA. Clinical outcomes during opioid titration following initiation with or conversion to Remoxy(R), an extended-release formulation of oxycodone. Postgrad Med. 2011; 123(4): 148-59[DOI][PubMed]
  • 21. Friedmann N, Klutzaritz V, Webster L. Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag. 2011; 7(3): 193-202[PubMed]
  • 22. Grella SL, Levy A, Campbell A, Djazayeri S, Allen CP, Goddard B, et al. Oxycodone dose-dependently imparts conditioned reinforcing properties to discrete sensory stimuli in rats. Pharmacol Res. 2011; 64(4): 364-70[DOI][PubMed]
  • 23. Mercadante S, Ferrera P, Adile C. High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer. 2011; 19(9): 1471-2[DOI][PubMed]
  • 24. Siniscalchi A, Gallelli L, Avenoso T, Squillace A, De Sarro G. Effects of carbamazepine/oxycodone coadministration in the treatment of trigeminal neuralgia. Ann Pharmacother. 2011; 45(6)[DOI][PubMed]
  • 25. Zacny JP, Gutierrez S. Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers. Psychopharmacology (Berl). 2011; 218(3): 471-81[DOI][PubMed]
  • 26. Gatti A, Longo G, Sabato E, Sabato AF. Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. Eur Neurol. 2011; 65(6): 317-22[DOI][PubMed]
  • 27. Anastassopoulos KP, Chow W, Ackerman SJ, Tapia C, Benson C, Kim MS. Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. J Opioid Manag. 2011; 7(3): 203-15[PubMed]
  • 28. Kral LA. Commonsense oxycodone prescribing and safety. 2007;
  • 29. Gooch CM, Rakitin BC, Cooper ZD, Comer SD, Balsam PD. Oxycodone lengthens reproductions of suprasecond time intervals in human research volunteers. Behav Pharmacol. 2011; 22(4): 354-61[DOI][PubMed]
  • 30. CESAR: Center for Substance Abuse Research. Oxycodone .
  • 31. Rao R, Desai NS. OxyContin and neonatal abstinence syndrome. J Perinatol. 2002; 22(4): 324-5[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments